L’inflammasome NLRP3 : physiopathologie et application thérapeutique - Université de Rennes Access content directly
Journal Articles La Presse Médicale Year : 2016

L’inflammasome NLRP3 : physiopathologie et application thérapeutique [The NLRP3 inflammasome: Physiopathology and therapeutic application]

L’inflammasome NLRP3 : physiopathologie et application thérapeutique

Sacha Robert
  • Function : Author
  • PersonId : 773621
  • IdRef : 199613230
Tatiana Victoni


The innate immune system constitutes the first line of host defense against pathogens. "Nonself", such as exogenous particles or pathogens, triggers an inflammatory response. Inflammasomes are molecular platforms activated upon cellular infection or stress that trigger the maturation of proinflammatory cytokines such as IL-1β. Activation of the NLRP3 inflammasome pathway, the most extensively studied, appears to be the corner stone of many inflammatory diseases, including Crohn's disease, rheumatoid arthritis and gout. Cryopyrine-associated periodic syndromes (CAPS) are NLRP3 inflammasome-associated diseases. Canakinumab (Ilaris(®)) is the only drug approved for CAPS treatment in France. Targeted therapy against NLRP3 inflammasome and IL-1β might be the new anti-inflammatory drugs.


Fichier principal
Vignette du fichier
Gicquel_NLRP3_Press_Med_2016.pdf (416.62 Ko) Télécharger le fichier
Origin : Files produced by the author(s)

Dates and versions

hal-01274225 , version 1 (29-09-2016)



Thomas Gicquel, Sacha Robert, Tatiana Victoni, Vincent Lagente. L’inflammasome NLRP3 : physiopathologie et application thérapeutique. La Presse Médicale, 2016, 45 (4, part 1), pp.438-446. ⟨10.1016/j.lpm.2016.01.006⟩. ⟨hal-01274225⟩
271 View
1284 Download



Gmail Facebook Twitter LinkedIn More